EGLN1 Genotype

If your blood work has ever shown a stubbornly high red blood cell count with no clear explanation, part of the answer may be written into a single gene that controls how your body senses oxygen. This test reads the version of that gene you were born with.

Most people will never need to think about it. But in a small number of families, the inherited version pushes red blood cell production too high, and in others it shapes how well the body copes with thin mountain air.

The Gene That Reads Your Oxygen Level

EGLN1 (egl-9 family hypoxia-inducible factor 1) is a gene, which means it is a stretch of DNA that carries the recipe for building a specific protein. The protein it builds is an enzyme called PHD2 (prolyl hydroxylase domain protein 2), one of your body's main oxygen sensors.

When oxygen is plentiful, PHD2 tags a signaling protein called HIF (hypoxia-inducible factor) for destruction, keeping it low. When oxygen drops, PHD2 eases off, HIF builds up, and switches on genes that make more red blood cells, grow new blood vessels, and shift how cells burn fuel. This whole system is the HIF oxygen-sensing pathway, and EGLN1 sits at its control point.

Because you inherit two copies of EGLN1, one from each parent, the exact spelling of your copies can tune how sensitive this switch is. That is what this test reads: the version of the gene you carry, not a level that rises and falls day to day.

Hereditary Erythrocytosis

The clearest disease link is a rare inherited condition where the body makes too many red blood cells, called erythrocytosis. When a damaging EGLN1 variant weakens the PHD2 enzyme, the HIF switch stays partly on even when oxygen is normal, and the body keeps signaling for more red cells. Thicker blood can raise the risk of clots.

A European study of 2,160 people with erythrocytosis catalogued the variants they carried. Only 16 variants, found in 48 patients and relatives, could be confidently called disease-causing, while many others could not be classified with certainty. Separate reports of rare families show that certain EGLN1 changes destabilize the PHD2 protein enough to produce lifelong erythrocytosis alongside clotting events.

One caution stands out: in that European group, people carrying confirmed disease-causing variants did not have clearly worse blood counts or more clots than people carrying variants of uncertain meaning. Clotting was no more common in the confirmed carriers than in the uncertain ones, a difference that was not clear-cut. Finding a variant does not, by itself, tell you how severe things will be.

Why a High Count Is Not the Whole Story

Here is the part that surprises people. Some EGLN1 variants push red blood cell counts up and cause disease, while others do the opposite. Tibetan highlanders carry a distinctive EGLN1 version linked to lower hemoglobin and protection from making too many red cells at altitude. This is not a simple good-number, bad-number gene. It is a phenotype gene, meaning different inherited versions steer your oxygen biology in different directions, and the same gene can be protective in one variant and harmful in another. That is why the specific variant you carry, not just the fact that EGLN1 is involved, is what matters.

High-Altitude Adaptation and Illness

EGLN1 is one of the most consistently identified genes in human adaptation to high altitude. Tibetans living even at sea level show a blunted HIF system, with weaker red blood cell responses to low oxygen. Andean and Quechua populations carry different EGLN1 variants that appear to help in their own way. In Peruvian Quechua, five EGLN1 variants were tied to higher peak oxygen use during exercise in thin air, with genotype differences of around 11%.

The flip side is trouble at altitude for people who lack these adaptations. In studies of high-altitude pulmonary edema (a dangerous buildup of fluid in the lungs at altitude, abbreviated HAPE), one EGLN1 variant known as rs479200 in its TT form was far more common in affected patients than in altitude-native populations, in whom it was nearly absent, and tracked with higher EGLN1 activity and lower blood oxygen. Related EGLN1 variants have also been associated with acute mountain sickness and with reduced cardiorespiratory fitness at altitude.

Emerging and Unproven Links

Beyond blood and altitude, a handful of early studies have reported other associations, and these should be read with caution. In one 158-person study in India, the C form of rs479200 was linked to about six times higher odds of severe COVID-19. In a separate study of about 100 oral cancer cases, the same variant was tied to roughly 60% higher odds of the disease.

These findings come from single populations, small samples, and one condition at a time. A study of severe sepsis found no link between EGLN1 variants and survival. Treat this category as interesting but far from established, not as a reason for alarm.

A Result You Only Need Once

Your genotype does not change over your lifetime, so this is a one-time test. There is no trend to track and no reason to repeat it unless a lab needs to confirm an unexpected result by a second method. The value comes not from retesting the gene, but from what you do with the answer over the years that follow.

If you carry a variant tied to erythrocytosis, the numbers worth watching over time are downstream blood measurements, not the gene itself. A complete blood count that includes hematocrit and hemoglobin, checked periodically, is what actually reflects whether your red cell mass is drifting high. Think of the genotype as the reason to keep an eye on those counts, with a sensible cadence of at least once a year if a meaningful variant is found.

What to Do If You Carry a Variant

A single gene result should never be the end of the conversation. If a potentially significant EGLN1 variant turns up, the next step is to look at the blood itself: order a complete blood count with hematocrit and hemoglobin, and consider an erythropoietin level (the hormone that drives red blood cell production). The combination of a suspicious variant plus a genuinely high, unexplained red cell count is what warrants action, not the gene finding alone.

This is territory for a hematologist (a blood specialist) or a medical geneticist, especially because polycythemia vera and other secondary causes of high counts need to be ruled out first. If the variant is labeled uncertain, that is common and not a diagnosis. If erythrocytosis runs in your family, a specialist can advise which relatives may benefit from targeted testing rather than broad screening.

Why This Result Can Mislead You

Genetic tests carry their own traps, and a clean-looking report can still mislead:

• Panel coverage: the assay only detects the specific variants it is built to detect. A negative result does not rule out other rare changes in EGLN1, because disease-causing mutations are scattered across the whole gene with no single hotspot.
• Ancestry matters: many EGLN1 variants were first described in specific populations, such as Tibetan, Andean, or Indian cohorts. A variant that is meaningful in one ancestry may be common and harmless in another, so the clinical weight of a result depends on where your ancestors came from.
• Uncertain variants: a large share of EGLN1 findings are variants of uncertain significance, meaning the science cannot yet say whether they cause disease. Reported reclassification rates for genetic variants in general range widely, so an uncertain label today can change later.
• Test grade: a clinical-grade genotype from a diagnostic lab is not the same as a consumer-style report for the same position, and germline testing assumes the DNA sample is not contaminated by another source.

The practical takeaway is that an EGLN1 result is a starting point for a conversation with a clinician, not a verdict. Its meaning depends heavily on the exact variant, your ancestry, and what your blood counts actually show.